The pathobiology of pig-to-primate xenotransplantation: A historical review

Xenotransplantation

Volumn 23, Issue 2, 2016, Pages 83-105

  Cooper, David K C ^a   Ezzelarab, Mohamed B ^a   Hara, Hidetaka ^a   Iwase, Hayato ^a   Lee, Whayoung ^a   Wijkstrom, Martin ^a   Bottino, Rita ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b ALLEGHENY SINGER RESEARCH INSTITUTE   (United States)

Author keywords

islets; Non human primate; organs; Pathobiology; Pig; Xenotransplantation

Indexed keywords

5' NUCLEOTIDASE; C REACTIVE PROTEIN; CD28 ANTIGEN; CD39 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; COMPLEMENT COMPONENT C3B RECEPTOR; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECAY ACCELERATING FACTOR; ENDOTHELIAL PROTEIN C RECEPTOR; FIBRINOGEN; GALACTOSYLGALACTOSE; HEME OXYGENASE 1; HLA E ANTIGEN; HLA G ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE COFACTOR PROTEIN; MYCOPHENOLATE MOFETIL; N ACETYLGALACTOSAMINYLTRANSFERASE; P SELECTIN GLYCOPROTEIN LIGAND 1; PROTEIN C; TACROLIMUS; THROMBOMODULIN; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ADAPTIVE IMMUNITY; ANTIBODY AFFINITY; BLOOD GROUP ABO INCOMPATIBILITY; CELL TRANSPLANTATION; CRISPR CAS SYSTEM; GENETIC ENGINEERING; GRAFT SURVIVAL; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPREGULATION; XENOTRANSPLANTATION; ANIMAL; GRAFT REJECTION; IMMUNOLOGY; PATHOLOGY; PIG; PRIMATE; PROCEDURES; TRANSGENIC ANIMAL; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; PRIMATES; SUS SCROFA; TRANSPLANTATION, HETEROLOGOUS;

EID: 84964299215     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12219     Document Type: Review

References (374)

1. Najarian JS,. Experimental xenotransplantation: a personal history. Xenotransplantation 2003; 10: 10-15.
2. Tector AJ, Chen X, Soderland C, Tchervenkov JI,. Complement activation in discordant hepatic xenotransplantation. Xenotransplantation 1998; 5: 257-261.
3. Tector AJ, Fridell JA, Watanabe T, et al., Pulmonary injury in recipients of discordant hepatic and renal xenografts in the dog-to-pig model. Xenotransplantation 1998; 5: 44-49.
4. Tector AJ, Fridell JA, Elias N, et al., Aberrations in hemostasis and coagulation in untreated discordant hepatic xenotransplantation: studies in the dog-to-pig model. Liver Transpl 2002; 8: 153-159.
5. Tector AJ, Fridell JA, Ruiz P, et al., Experimental discordant hepatic xenotransplantation in the recipient with liver failure: implications for clinical bridging trials. J Am Coll Surg 2000; 191: 54-64.
6. Baker J, Martin M, Ye Y, et al., Presence of a complement-dependent "cytotoxic factor" in dog serum: relevance to experimental discordant xenotransplantation. Transplant Proc 1992; 24: 490-491.
7. Ye Y, Cooper DK, Niekrasz M, et al., Removal of dog antipig antibody by adsorption with pig red blood cell stroma columns. Transplant Proc 1992; 24: 563-565.
8. Lexer G, Cooper DK, Rose AG, et al., Hyperacute rejection in a discordant (pig to baboon) cardiac xenograft model. J Heart Transplant 1986; 5: 411-418.
9. Cooper DK, Human PA, Lexer G, et al., Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. J Heart Transplant 1988; 7: 238-246.
10. Cooper DKC, Rose AG,. Experience with experimental xenografting in primates. In:, Hardy MA, ed. Xenograft 25. Amsterdam, New York, Oxford: Excerpta Medica, 1989: 95-105.
11. Alexandre GPJ, Gianello P, Latinne D, et al., Plasmapheresis and splenectomy in experimental renal xenotransplantation. In:, Hardy M, ed. Xenograft 25. Amsterdam, New York, Oxford: Excerpta Medica, 1989: 259-266.
12. Taniguchi S, Cooper DK,. Clinical xenotransplantation: past, present and future. Ann R Coll Surg Engl 1997; 79: 13-19.
13. Cooper DK,. A brief history of cross-species organ transplantation. Proc (Bayl Univ Med Cent) 2012; 25: 49-57.
14. Cooper DK, Satyananda V, Ekser B, et al., Progress in pig-to-nonhuman primate transplantation models (1998-2013): a comprehensive review of the literature. Xenotransplantation 2014; 21: 397-419.
15. Lambrigts D, Sachs DH, Cooper DK,. Discordant organ xenotransplantation in primates: world experience and current status. Transplantation 1998; 66: 547-561.
16. Rose AG, Cooper DK, Human PA, Reichenspurner H, Reichart B,. Histopathology of hyperacute rejection of the heart: experimental and clinical observations in allografts and xenografts. J Heart Lung Transplant 1991; 10: 223-234.
17. Rose AG, Cooper DK,. A histopathologic grading system of hyperacute (humoral, antibody-mediated) cardiac xenograft and allograft rejection. J Heart Lung Transplant 1996; 15: 804-817.
18. Rose AG, Cooper DK,. Venular thrombosis is the key event in the pathogenesis of antibody-mediated cardiac rejection. Xenotransplantation 2000; 7: 31-41.
19. Leventhal JR, Dalmasso AP, Cromwell JW, et al., Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857-865; discussion 865-856.
20. Leventhal JR, Sakiyalak P, Witson J, et al., The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation 1994; 57: 974-978.
21. Kobayashi T, Neethling FA, Taniguchi S, et al., Investigation of the anti-complement agnets, FUT-175 and K76COOH, in discordant xenotransplantation. Xenotransplantation 1996; 3: 237-245.
22. Kobayashi T, Taniguchi S, Neethling FA, et al., Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation 1997; 64: 1255-1261.
23. Pruitt SK, Kirk AD, Bollinger RR, et al., The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363-370.
24. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH,. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52: 530-533.
25. White DJ, Oglesby T, Liszewski MK, et al., Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transpl Int 1992; 5 (Suppl 1): S648-S650.
26. White DJG, Langford GA, Cozzi E, Young VK,. Production of pigs trangenic for human DAF: a strategy for xenotransplantation. Xenotransplantation 1995; 2: 213-217.
27. Oglesby TJ, Allen CJ, Liszewski MK, White DJ, Atkinson JP,. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 1992; 175: 1547-1551.
28. Walsh LA, Tone M, Waldmann H,. Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement. Eur J Immunol 1991; 21: 847-850.
29. Atkinson JP, Oglesby TJ, White D, Adams EA, Liszewski MK,. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin Exp Immunol 1991; 86 (Suppl 1): 27-30.
30. Morgan BP, Berg CW, Harris CL,. "Homologous restriction" in complement lysis: roles of membrane complement regulators. Xenotransplantation 2005; 12: 258-265.
31. Langford GA, Yannoutsos N, Cozzi E, et al., Production of pigs transgenic for human decay accelerating factor. Transplant Proc 1994; 26: 1400-1401.
32. Cozzi E, White DJ,. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964-966.
33. Fodor WL, Williams BL, Matis LA, et al., Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153-11157.
34. Rosengard AM, Cary NR, Langford GA, et al., Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. A potential approach for preventing xenograft rejection. Transplantation 1995; 59: 1325-1333.
35. McCurry KR, Kooyman DL, Alvarado CG, et al., Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1: 423-427.
36. Diamond LE, McCurry KR, Martin MJ, et al., Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996; 61: 1241-1249.
37. Loveland BE, Milland J, Kyriakou P, et al., Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons. Xenotransplantation 2004; 11: 171-183.
38. Cozzi E, Yannoutsos N, Langford GA, et al., Effects of transgenic expression of human decay accelerating factor on the inhibition of hyperacute rejection of pig organs. In:, Cooper D, Kemp E, Platt JL, White DJG, eds. Xenotransplantation-the transplantation of organs and tissues between species. 2nd ed. Berlin: Springer, 1997; 665-682.
39. Cozzi E, Langford GA, Richards A, et al., Expression of human decay accelerating factor in transgenic pigs. Transplant Proc 1994; 26: 1402-1403.
40. Schuurman HJ, Pino-Chavez G, Phillips MJ, et al., Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors. Transplantation 2002; 73: 1146-1151.
41. Schuurman HJ, Cheng J, Lam T,. Pathology of xenograft rejection: a commentary. Xenotransplantation 2003; 10: 293-299.
42. Alexandre GP, de Bruyere M, Squifflet JP, et al., Human ABO-incompatible living donor renal homografts. Neth J Med 1985; 28: 231-234.
43. Alexandre GP, Squifflet JP, de Bruyere M, et al., Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19: 4538-4542.
44. Alexandre GP,. From ABO-incompatible human kidney transplantation to xenotransplantation. Xenotransplantation 2004; 11: 233-236.
45. Stussi G, West L, Cooper DK, Seebach JD,. ABO-incompatible allotransplantation as a basis for clinical xenotransplantation. Xenotransplantation 2006; 13: 390-399.
46. Good AH, Cooper DK, Malcolm AJ, et al., Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992; 24: 559-562.
47. Cooper DK,. Depletion of natural antibodies in non-human primates-a step towards successful discordant xenografting in humans. Clin Transplant 1992; 6: 178-183.
48. Cooper DK, Good AH, Koren E, et al., Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol 1993; 1: 198-205.
49. Koren E, Neethling FA, Richards S, et al., Binding and specificity of major immunoglobulin classes of preformed human anti-pig heart antibodies. Transpl Int 1993; 6: 351-353.
50. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IF,. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391-11395.
51. Cooper DK,. Identification of alpha Gal as the major target for human anti-pig antibodies. Xenotransplantation 2009; 16: 47-49.
52. Kujundzic M, Koren E, Neethling FA, et al., Variability of anti-alphaGal antibodies in human serum and their relation to serum cytotoxicity against pig cells. Xenotransplantation 1994; 1: 58-65.
53. Kobayashi T, Cooper DK,. Anti-Gal, alpha-Gal epitopes, and xenotransplantation. Subcell Biochem 1999; 32: 229-257.
54. Cooper DK, Koren E, Oriol R,. Oligosaccharides and discordant xenotransplantation. Immunol Rev 1994; 141: 31-58.
55. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA,. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 1988; 263: 17755-17762.
56. Oriol R, Ye Y, Koren E, Cooper DK,. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation 1993; 56: 1433-1442.
57. Oriol R, Barthod F, Bergemer AM, et al., Monomorphic and polymorphic carbohydrate antigens on pig tissues: implications for organ xenotransplantation in the pig-to-human model. Transpl Int 1994; 7: 405-413.
58. McKenzie IF, Xing PX, Vaughan HA, et al., Distribution of the major xenoantigen (gal (alpha 1-3)gal) for pig to human xenografts. Transpl Immunol 1994; 2: 81-86.
59. Galili U,. Evolution of alpha 1,3galactosyltransferase and of the alpha-Gal epitope. Subcell Biochem 1999; 32: 1-23.
60. Koike C, Uddin M, Wildman DE, et al., Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci USA 2007; 104: 559-564.
61. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM,. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988; 56: 1730-1737.
62. Rood PP, Tai HC, Hara H, et al., Late onset of development of natural anti-nonGal antibodies in infant humans and baboons: implications for xenotransplantation in infants. Transpl Int 2007; 20: 1050-1058.
63. Dons EM, Montoya C, Long CE, et al., T-cell-based immunosuppressive therapy inhibits the development of natural antibodies in infant baboons. Transplantation 2012; 93: 769-776.
64. Neethling F, Cooper DK, Xu H, Michler RE,. Newborn baboon serum anti-alpha galactosyl antibody levels and cytotoxicity to cultured pig kidney (PK15) cells. Transplantation 1995; 60: 520-521.
65. Minanov OP, Itescu S, Neethling FA, et al., Anti-GaL IgG antibodies in sera of newborn humans and baboons and its significance in pig xenotransplantation. Transplantation 1997; 63: 182-186.
66. Mohiuddin MM, Corcoran PC, Singh AK, et al., B-cell depletion extends the survival of GTKO.hCD46Tg pig heart xenografts in baboons for up to 8 months. Am J Transplant 2012; 12: 763-771.
67. Zhou H, Iwase H, Wolf RF, et al., Are there advantages in the use of specific pathogen-free baboons in pig organ xenotransplantation models? Xenotransplantation 2014; 21: 287-290.
68. Cretin N, Bracy J, Hanson K, Iacomini J,. The role of T cell help in the production of antibodies specific for Gal alpha 1-3Gal. J Immunol 2002; 168: 1479-1483.
69. Alwayn IP, Basker M, Buhler L, Cooper DK,. The problem of anti-pig antibodies in pig-to-primate xenografting: current and novel methods of depletion and/or suppression of production of anti-pig antibodies. Xenotransplantation 1999; 6: 157-168.
70. Cooper DK, Ye Y, Niekrasz M, et al., Specific intravenous carbohydrate therapy. A new concept in inhibiting antibody-mediated rejection-experience with ABO-incompatible cardiac allografting in the baboon. Transplantation 1993; 56: 769-777.
71. Ye Y, Niekrasz M, Kehoe M, et al., Cardiac allotransplantation across the ABO-blood group barrier by the neutralization of preformed antibodies: the baboon as a model for the human. Lab Anim Sci 1994; 44: 121-124.
72. Ye Y, Neethling FA, Niekrasz M, et al., Evidence that intravenously administered alpha-galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK15) and transplanted pig hearts. Transplantation 1994; 58: 330-337.
73. Simon PM, Neethling FA, Taniguchi S, et al., Intravenous infusion of Galalpha1-3Gal oligosaccharides in baboons delays hyperacute rejection of porcine heart xenografts. Transplantation 1998; 65: 346-353.
74. Romano E, Neethling FA, Nilsson K, et al., Intravenous synthetic alphaGal saccharides delay hyperacute rejection following pig-to-baboon heart transplantation. Xenotransplantation 1999; 6: 36-42.
75. Teranishi K, Alwayn IP, Buhler L, et al., Depletion of anti-Gal antibodies by the intravenous infusion of Gal type 2 and 6 glycoconjugates in baboons. Xenotransplantation 2003; 10: 357-367.
76. Teranishi K, Gollackner B, Buhler L, et al., Depletion of anti-gal antibodies in baboons by intravenous therapy with bovine serum albumin conjugated to gal oligosaccharides. Transplantation 2002; 73: 129-139.
77. Kuwaki K, Knosalla C, Moran K, et al., Reduction of anti-Galalpha 1,3Gal antibodies by infusion of types 2 and 6 gal trisaccharides conjugated to poly-L-lysine. Xenotransplantation 2004; 11: 210-215.
78. Rieben R, von Allmen E, Korchagina EY, et al., Detection, immunoabsorption, and inhibition of cytotoxic activity of anti-alphaGal antibodies using newly developed substances with synthetic Gal alpha1-3Gal disaccharide epitopes. Xenotransplantation 1995; 2: 98-106.
79. Neethling FA, Koren E, Ye Y, et al., Protection of pig kidney (PK15) cells from the cytotoxic effect of anti-pig antibodies by alpha-galactosyl oligosaccharides. Transplantation 1994; 57: 959-963.
80. Neethling FA, Joziasse D, Bovin N, Cooper DK, Oriol R,. The reducing end of alpha Gal oligosaccharides contributes to their efficiency in blocking natural antibodies of human and baboon sera. Transpl Int 1996; 9: 98-101.
81. Neethling FA, Cooper DK,. Serum cytotoxicity to pig cells and anti-alphaGal antibody level and specificity in humans and baboons. Transplantation 1999; 67: 658-665.
82. Gollackner B, Knosalla C, Houser S, et al., Pig kidney transplantation in baboons treated intravenously with a bovine serum albumin-Galalpha1-3Gal conjugate. Xenotransplantation 2003; 10: 606-614.
83. Ierino FL, Kozlowski T, Siegel JB, et al., Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts. Transplantation 1998; 66: 1439-1450.
84. Kozlowski T, Ierino FL, Lambrigts D, et al., Depletion of anti-Gal(alpha)1-3Gal antibody in baboons by specific alpha-Gal immunoaffinity columns. Xenotransplantation 1998; 5: 122-131.
85. Xu Y, Lorf T, Sablinski T, et al., Removal of anti-porcine natural antibodies from human and nonhuman primate plasma in vitro and in vivo by a Galalpha1-3Galbeta1-4betaGlc-X immunoaffinity column. Transplantation 1998; 65: 172-179.
86. Taniguchi S, Neethling FA, Korchagina EY, et al., In vivo immunoadsorption of antipig antibodies in baboons using a specific Gal(alpha)1-3Gal column. Transplantation 1996; 62: 1379-1384.
87. Lambrigts D, van Calster P, Xu Y, et al., Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of anti-alphaGal antibody in the baboon. Xenotransplantation 1998; 5: 274-283.
88. Kozlowski T, Shimizu A, Lambrigts D, et al., Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption. Transplantation 1999; 67: 18-30.
89. Cooper DK, Cairns TD, Taube DH,. Extracorporeal immunoadsorption of alphaGal antibodies. Xeno 1996; 4: 27-29.
90. Watts A, Foley A, Awwad M, et al., Plasma perfusion by apheresis through a Gal immunoaffinity column successfully depletes anti-Gal antibody: experience with 320 aphereses in baboons. Xenotransplantation 2000; 7: 181-185.
91. Cooper DK, Koren E, Oriol R,. Genetically engineered pigs. Lancet 1993; 342: 682-683.
92. Thall AD, Maly P, Lowe JB,. Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 1995; 270: 21437-21440.
93. Tearle RG, Tange MJ, Zannettino ZL, et al., The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation 1996; 61: 13-19.
94. McKenzie IF, Li YQ, Patton K, Thall AD, Sandrin MS,. A murine model of antibody-mediated hyperacute rejection by galactose-alpha(1,3)galactose antibodies in Gal o/o mice. Transplantation 1998; 66: 754-763.
95. Campbell KH, McWhir J, Ritchie WA, Wilmut I,. Sheep cloned by nuclear transfer from a cultured cell line. Nature 1996; 380: 64-66.
96. Polejaeva IA, Chen SH, Vaught TD, et al., Cloned pigs produced by nuclear transfer from adult somatic cells. Nature 2000; 407: 86-90.
97. Koike C, Fung JJ, Geller DA, et al., Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase gene in higher primates. J Biol Chem 2002; 277: 10114-10120.
98. Phelps CJ, Koike C, Vaught TD, et al., Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411-414.
99. Kolber-Simonds D, Lai L, Watt SR, et al., Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci USA 2004; 101: 7335-7340.
100. Kuwaki K, Tseng YL, Dor FJ, et al., Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11: 29-31.
101. Tseng YL, Kuwaki K, Dor FJ, et al., alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation 2005; 80: 1493-1500.
102. Yamada K, Yazawa K, Shimizu A, et al., Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11: 32-34.
103. Shimizu A, Hisashi Y, Kuwaki K, et al., Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008; 172: 1471-1481.
104. Hisashi Y, Yamada K, Kuwaki K, et al., Rejection of cardiac xenografts transplanted from alpha1,3-galactosyltransferase gene-knockout (GalT-KO) pigs to baboons. Am J Transplant 2008; 8: 2516-2526.
105. Ezzelarab M, Garcia B, Azimzadeh A, et al., The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation 2009; 87: 805-812.
106. Chen G, Qian H, Starzl T, et al., Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005; 11: 1295-1298.
107. Baumann BC, Stussi G, Huggel K, et al., Reactivity of human natural antibodies to endothelial cells from Galalpha(1,3)Gal-deficient pigs. Transplantation 2007; 83: 193-201.
108. Rood PP, Hara H, Busch JL, et al., Incidence and cytotoxicity of antibodies in cynomolgus monkeys directed to nonGal antigens, and their relevance for experimental models. Transpl Int 2006; 19: 158-165.
109. Rood PP, Hara H, Ezzelarab M, et al., Preformed antibodies to alpha1,3-galactosyltransferase gene-knockout (GT-KO) pig cells in humans, baboons, and monkeys: implications for xenotransplantation. Transplant Proc 2005; 37: 3514-3515.
110. Ezzelarab M, Hara H, Busch J, et al., Antibodies directed to pig non-Gal antigens in naive and sensitized baboons. Xenotransplantation 2006; 13: 400-407.
111. Tseng YL, Moran K, Dor FJ, et al., Elicited antibodies in baboons exposed to tissues from alpha1,3-galactosyltransferase gene-knockout pigs. Transplantation 2006; 81: 1058-1062.
112. Cooper DK,. Xenoantigens and xenoantibodies. Xenotransplantation 1998; 5: 6-17.
113. Ezzelarab M, Ayares D, Cooper DK,. Carbohydrates in xenotransplantation. Immunol Cell Biol 2005; 83: 396-404.
114. Yeh P, Ezzelarab M, Bovin N, et al., Investigation of potential carbohydrate antigen targets for human and baboon antibodies. Xenotransplantation 2010; 17: 197-206.
115. Byrne GW, Du Z, Stalboerger P, Kogelberg H, McGregor CG,. Cloning and expression of porcine beta1,4 N-acetylgalactosaminyl transferase encoding a new xenoreactive antigen. Xenotransplantation 2014; 21: 543-554.
116. Byrne GW, Azimzadeh AM, Ezzelarab M, et al., Histopathologic insights into the mechanism of anti-non-Gal antibody-mediated pig cardiac xenograft rejection. Xenotransplantation 2013; 20: 292-307.
117. Hara H, Long C, Lin YJ, et al., In vitro investigation of pig cells for resistance to human antibody-mediated rejection. Transpl Int 2008; 21: 1163-1174.
118. Azimzadeh A, Kelishadi S, Ezzelarab M, et al., Early graft failure of GTKO pig organs in baboons is reduced in hCPRP expression. Xenotransplantation 2009; 16: 356 (Abstract).
119. Azimzadeh A, Kelishadi S, Ezzelarab MB, et al., Early graft failure of GalTKO pig organs in baboons is reduced by expression of a human complement-regulatory protein. Xenotransplantation 2015; 22: 310-316.
120. McGregor CG, Ricci D, Miyagi N, et al., Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts. Transplantation 2012; 93: 686-692.
121. van Denderen BJ, Salvaris E, Romanella M, et al., Combination of decay-accelerating factor expression and alpha1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury. Transplantation 1997; 64: 882-888.
122. Gollackner B, Goh SK, Qawi I, et al., Acute vascular rejection of xenografts: roles of natural and elicited xenoreactive antibodies in activation of vascular endothelial cells and induction of procoagulant activity. Transplantation 2004; 77: 1735-1741.
123. Lin SS, Weidner BC, Byrne GW, et al., The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745-1756.
124. Buhler L, Awwad M, Basker M, et al., High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. Transplantation 2000; 69: 2296-2304.
125. Chen G, Sun H, Yang H, et al., The role of anti-non-Gal antibodies in the development of acute humoral xenograft rejection of hDAF transgenic porcine kidneys in baboons receiving anti-Gal antibody neutralization therapy. Transplantation 2006; 81: 273-283.
126. Ezzelarab C, Ayares D, Cooper DK, Ezzelarab MB,. Human T-cell proliferation in response to thrombin-activated GTKO pig endothelial cells. Xenotransplantation 2012; 19: 311-316.
127. Cozzi E, Vial C, Ostlie D, et al., Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts. Xenotransplantation 2003; 10: 300-310.
128. McGregor CG, Davies WR, Oi K, et al., Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130: 844-851.
129. McGregor CG, Teotia SS, Byrne GW, et al., Cardiac xenotransplantation: progress toward the clinic. Transplantation 2004; 78: 1569-1575.
130. Teotia SS, Walker RC, Schirmer JM, et al., Prevention, detection, and management of early bacterial and fungal infections in a preclinical cardiac xenotransplantation model that achieves prolonged survival. Xenotransplantation 2005; 12: 127-133.
131. Ezzelarab MB, Ekser B, Echeverri G, et al., Costimulation blockade in pig artery patch xenotransplantation-a simple model to monitor the adaptive immune response in nonhuman primates. Xenotransplantation 2012; 19: 221-232.
132. Mohiuddin MM, Singh AK, Corcoran PC, et al., Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation. J Thorac Cardiovasc Surg 2014; 148: 1106-1113; discussion 1113-1104.
133. Mohiuddin MM, Singh AK, Corcoran PC, et al., Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model. Xenotransplantation 2014; 21: 35-45.
134. Mohiuddin MM, Singh AK, Corcoran PC, et al., One-year heterotopic cardiac xenograft survival in a pig to baboon model. Am J Transplant 2014; 14: 488-489.
135. Iwase H, Ekser B, Satyananda V, et al., Pig-to-baboon heart transplantation-first experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens. Xenotransplantation 2015; 22: 211-220.
136. Iwase H, Liu H, Wijkstrom M, et al., Pig kidney graft survival in a baboon for 136 days: longest life-supporting organ graft survival to date. Xenotransplantation 2015; 22: 302-309.
137. Iwase H, Satyananda V, Zhou H, et al., Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigs. Transpl Immunol 2015; 32: 99-108.
138. Higginbotham L, Mathews D, Breeden CA, et al., Pre-transplant antibody screening and anti-CD154 costimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model. Xenotransplantation 2015; 22: 221-230.
139. Kuwaki K, Knosalla C, Dor FJ, et al., Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004; 4: 363-372.
140. Knosalla C, Ryan DJ, Moran K, et al., Initial experience with the human anti-human CD154 monoclonal antibody, ABI793, in pig-to-baboon xenotransplantation. Xenotransplantation 2004; 11: 353-360.
141. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB,. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
142. Kirk AD, Knechtle SJ, Sollinger HW,. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am J Transplant 2001; 1 (Suppl 1): 191 (Abstract).
143. Knosalla C, Gollackner B, Cooper DK,. Anti-CD154 monoclonal antibody and thromboembolism revisted. Transplantation 2002; 74: 416-417.
144. Lee RS, Yamada K, Womer KL, et al., Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses. J Immunol 2000; 164: 3434-3444.
145. Lee W, Satyananda V, Iwase H, et al., In vitro testing of an anti-CD40 monoclonal antibody, clone 2C10, in primates and pigs. Transpl Immunol 2015: 33, 185-191.
146. Ezzelarab MB, Ekser B, Azimzadeh A, et al., Systemic inflammation in xenograft recipients precedes activation of coagulation. Xenotransplantation 2015; 22: 32-47.
147. Ezzelarab MB, Ekser B, Isse K, et al., Increased soluble CD154 (CD40 ligand) levels in xenograft recipients correlate with the development of de novo anti-pig IgG antibodies. Transplantation 2014; 97: 502-508.
148. Alwayn IP, Xu Y, Basker M, et al., Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation 2001; 8: 157-171.
149. Satyananda V, Hara H, Ezzelarab MB, et al., New concepts of immune modulation in xenotransplantation. Transplantation 2013; 96: 937-945.
150. Cowan PJ, Cooper DK, D'Apice AJ,. Kidney xenotransplantation. Kidney Int 2014; 85: 265-275.
151. Wilhite T, Ezzelarab C, Hara H, et al., The effect of Gal expression on pig cells on the human T-cell xenoresponse. Xenotransplantation 2012; 19: 56-63.
152. Ezzelarab M, Ezzelarab C, Wilhite T, et al., Genetically-modified pig mesenchymal stromal cells: xenoantigenicity and effect on human T-cell xenoresponses. Xenotransplantation 2011; 18: 183-195.
153. Schubert T, Poilvache H, Galli C, Gianello P, Dufrane D,. Galactosyl-knock-out engineered pig as a xenogenic donor source of adipose MSCs for bone regeneration. Biomaterials 2013; 34: 3279-3289.
154. Ezzelarab MB, Ayares D, Cooper DK,. Transgenic expression of human CD46: does it reduce the primate T cell response to pig xenografts? Xenotransplantation 2015; 22: 487-489.
155. Phelps CJ, Ball SF, Vaught TD, et al., Production and characterization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation 2009; 16: 477-485.
156. Koshika T, Phelps C, Fang J, et al., Relative efficiency of porcine and human cytotoxic T-lymphocyte antigen 4 immunoglobulin in inhibiting human CD4+ T-cell responses co-stimulated by porcine and human B7 molecules. Immunology 2011; 134: 386-397.
157. Bottino R, Wijkstrom M, van der Windt DJ, et al., Pig-to-monkey islet xenotransplantation using multi-transgenic pigs. Am J Transplant 2014; 14: 2275-2287.
158. Hara H, Witt W, Crossley T, et al., Human dominant-negative class II transactivator transgenic pigs-effect on the human anti-pig T-cell immune response and immune status. Immunology 2013; 140: 39-46.
159. Reyes LM, Estrada JL, Wang ZY, et al., Creating class I MHC-null pigs using guide RNA and the Cas9 endonuclease. J Immunol 2014; 193: 5751-5757.
160. Inverardi L, Clissi B, Stolzer AL, et al., Human natural killer lymphocytes directly recognize evolutionarily conserved oligosaccharide ligands expressed by xenogeneic tissues. Transplantation 1997; 63: 1318-1330.
161. Baumann BC, Forte P, Hawley RJ, et al., Lack of galactose-alpha-1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol 2004; 172: 6460-6467.
162. Rieben R, Seebach JD,. Xenograft rejection: IgG1, complement and NK cells team up to activate and destroy the endothelium. Trends Immunol 2005; 26: 2-5.
163. Horvath-Arcidiacono JA, Porter CM, Bloom ET,. Human NK cells can lyse porcine endothelial cells independent of their expression of Galalpha(1,3)-Gal and killing is enhanced by activation of either effector or target cells. Xenotransplantation 2006; 13: 318-327.
164. Kennett SB, Porter CM, Horvath-Arcidiacono JA, Bloom ET,. Characterization of baboon NK cells and their xenogeneic activity. Xenotransplantation 2010; 17: 288-299.
165. Sasaki H, Xu XC, Smith DM, Howard T, Mohanakumar T,. HLA-G expression protects porcine endothelial cells against natural killer cell-mediated xenogeneic cytotoxicity. Transplantation 1999; 67: 31-37.
166. Dorling A, Monk N, Lechler R,. HLA-G inhibits the transendothelial cell migration of human NK cells: a strategy for inhibiting xenograft rejection. Transplant Proc 2000; 32: 938.
167. Matsunami K, Miyagawa S, Nakai R, Murase A, Shirakura R,. The possible use of HLA-G1 and G3 in the inhibition of NK cell-mediated swine endothelial cell lysis. Clin Exp Immunol 2001; 126: 165-172.
168. Forte P, Pazmany L, Matter-Reissmann UB, et al., HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells. J Immunol 2001; 167: 6002-6008.
169. Forte P, Baumann BC, Weiss EH, Seebach JD,. HLA-E expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading. Am J Transplant 2005; 5: 2085-2093.
170. Crew MD,. Play it in E or G: utilization of HLA-E and -G in xenotransplantation. Xenotransplantation 2007; 14: 198-207.
171. Seebach JD, Comrack C, Germana S, et al., HLA-Cw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells. J Immunol 1997; 159: 3655-3661.
172. Weiss EH, Lilienfeld BG, Muller S, et al., HLA-E/human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. Transplantation 2009; 87: 35-43.
173. Maeda A, Kawamura T, Ueno T, et al., The suppression of inflammatory macrophage-mediated cytotoxicity and proinflammatory cytokine production by transgenic expression of HLA-E. Transpl Immunol 2013; 29: 76-81.
174. Esquivel EL, Maeda A, Eguchi H, et al., Suppression of human macrophage-mediated cytotoxicity by transgenic swine endothelial cell expression of HLA-G. Transpl Immunol 2015; 32: 109-115.
175. Platt JL, Vercellotti GM, Lindman BJ, et al., Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 1990: 171: 1363-1368.
176. Bach FH, Robson SC, Ferran C, et al., Endothelial cell activation and thromboregulation during xenograft rejection. Immunol Rev 1994; 141: 5-30.
177. Kopp CW, Siegel JB, Hancock WW, et al., Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63: 749-758.
178. Kopp CW, Grey ST, Siegel JB, et al., Expression of human thrombomodulin cofactor activity in porcine endothelial cells. Transplantation 1998; 66: 244-251.
179. Lawson JH, Daniels LJ, Platt JL,. The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant Proc 1997; 29: 884-885.
180. Siegel JB, Grey ST, Lesnikoski BA, et al., Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64: 888-896.
181. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL,. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807-1814.
182. Buhler L, Basker M, Alwayn IP, et al., Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 2000; 70: 1323-1331.
183. Cowan PJ, Aminian A, Barlow H, et al., Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69: 2504-2515.
184. Buhler L, Yamada K, Kitamura H, et al., Pig kidney transplantation in baboons: anti-Gal(alpha)1-3Gal IgM alone is associated with acute humoral xenograft rejection and disseminated intravascular coagulation. Transplantation 2001; 72: 1743-1752.
185. Houser SL, Kuwaki K, Knosalla C, et al., Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 2004; 11: 416-425.
186. Lin CC, Ezzelarab M, Shapiro R, et al., Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transplant 2010; 10: 1556-1568.
187. Shimizu A, Yamada K, Yamamoto S, et al., Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol 2005; 16: 2732-2745.
188. Shimizu A, Yamada K, Robson SC, Sachs DH, Colvin RB,. Pathologic characteristics of transplanted kidney xenografts. J Am Soc Nephrol 2012; 23: 225-235.
189. Iwase H, Ekser B, Zhou H, et al., Platelet aggregation in humans and nonhuman primates: relevance to xenotransplantation. Xenotransplantation 2012; 19: 233-243.
190. Schulte AM, Esch J 2nd, Cruz MA, Siegel JB, Anrather J, Robson SC,. Activation of human platelets by the membrane-expressed A1 domain of von Willebrand factor. Blood 1997; 90: 4425-4437.
191. Robson SC, Young VK, Cook NS, et al., Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection. Transplantation 1996; 61: 862-868.
192. Ghanekar A, Mendicino M, Liu H, et al., Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol 2004; 172: 5693-5701.
193. Mendicino M, Liu M, Ghanekar A, et al., Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. Circulation 2005; 112: 248-256.
194. Lin CC, Chen D, McVey JH, Cooper DK, Dorling A,. Expression of tissue factor and initiation of clotting by human platelets and monocytes after incubation with porcine endothelial cells. Transplantation 2008; 86: 702-709.
195. Ezzelarab M, Liu YW, Lin CC, et al., Role of P-selectin and P-selectin glycoprotein ligand-1 interaction in the induction of tissue factor expression on human platelets after incubation with porcine aortic endothelial cells. Xenotransplantation 2014; 21: 15-24.
196. Robson SC, Cooper DK, D'Apice AJ,. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 2000; 7: 166-176.
197. Cowan PJ, Robson SC, D'Apice AJ,. Controlling coagulation dysregulation in xenotransplantation. Curr Opin Organ Transplant 2011; 16: 214-221.
198. Cowan PJ, D'Apice AJ,. The coagulation barrier in xenotransplantation: incompatibilities and strategies to overcome them. Curr Opin Organ Transplant 2008; 13: 178-183.
199. Cowan PJ, Roussel JC, D'Apice AJ,. The vascular and coagulation issues in xenotransplantation. Curr Opin Organ Transplant 2009; 14: 161-167.
200. Iwase H, Ezzelarab MB, Ekser B, Cooper DK,. The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options. Xenotransplantation 2014; 21: 201-220.
201. Schulte AM, Esch J,. 2 nd, R ogiers X, R obson SC. Molecular incompatibilities in hemostasis between swine and men-impact on xenografting. Ann Transplant 2001; 6: 12-16.
202. Dorling A, Lechler R,. Disordered thromboregulation after xenografting. Curr Opin Organ Transplant 2001; 6: 36-41.
203. Roussel JC, Moran CJ, Salvaris EJ, et al., Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008; 8: 1101-1112.
204. Lee KF, Salvaris EJ, Roussel JC, et al., Recombinant pig TFPI efficiently regulates human tissue factor pathways. Xenotransplantation 2008; 15: 191-197.
205. Knosalla C, Yazawa K, Behdad A, et al., Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig-to-baboon xenotransplantation. Am J Transplant 2009; 9: 1006-1016.
206. Schirmer JM, Fass DN, Byrne GW, et al., Effective antiplatelet therapy does not prolong transgenic pig to baboon cardiac xenograft survival. Xenotransplantation 2004; 11: 436-443.
207. Byrne GW, Schirmer JM, Fass DN, et al., Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 2005; 5: 1011-1020.
208. Byrne GW, Davies WR, Oi K, et al., Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival. Transplantation 2006; 82: 1787-1791.
209. Cooper DK, Ekser B, Burlak C, et al., Clinical lung xenotransplantation-what donor genetic modifications may be necessary? Xenotransplantation 2012; 19: 144-158.
210. Petersen B, Ramackers W, Tiede A, et al., Pigs transgenic for human thrombomodulin have elevated production of activated protein C. Xenotransplantation 2009; 16: 486-495.
211. Miwa Y, Yamamoto K, Onishi A, et al., Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation. Xenotransplantation 2010; 17: 26-37.
212. Klymiuk N, Wuensch A, Kurome M, et al., GalT-KO/CD46/hTM triple-transgenic donor animals for pig-to-baboon heart transplantation. Xenotransplantation 2011; 18: 271 (Abstract #126).
213. Yazaki S, Iwamoto M, Onishi A, et al., Production of cloned pigs expressing human thrombomodulin in endothelial cells. Xenotransplantation 2012; 19: 82-91.
214. Wuensch A, Baehr A, Bongoni AK, et al., Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- and multitransgenic pigs. Transplantation 2014; 97: 138-147.
215. Wrighton CJ, Kopp CW, McShea A, Vetr H, Bach FH,. High-level expression of functional human thrombomodulin in cultured porcine aortic endothelial cells. Transplant Proc 1995; 27: 288-289.
216. Kaczmarek E, Koziak K, Sevigny J, et al., Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996; 271: 33116-33122.
217. Smolenski R, Kochan Z, Karbowska J, et al., Low expression of ecto-5′-nucleotidase in the pig heart-a potential barrier to xenotransplantation. J Heart Lung Transplant 2001; 20: 214-215.
218. Smolenski RT, Khalpey Z, Yuen AC, et al., Purine metabolism in pigs and humans and its implications for xenotransplantation. Nucleosides, Nucleotides Nucleic Acids 2005; 24: 263-266.
219. Smolenski RT, Khalpey Z, Osborne FN, et al., Species differences of endothelial extracellular nucleotide metabolism and its implications for xenotransplantation. Pharmacol Rep 2006; 58 (Suppl): 118-125.
220. Deaglio S, Dwyer KM, Gao W, et al., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
221. Dwyer KM, Robson SC, Nandurkar HH, et al., Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113: 1440-1446.
222. Dwyer KM, Mysore TB, Crikis S, et al., The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation 2006; 82: 428-432.
223. Dwyer KM, Deaglio S, Gao W, et al., CD39 and control of cellular immune responses. Purinergic Signal 2007; 3: 171-180.
224. di Virgilio F, Boeynaems JM, Robson SC,. Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol 2009; 9: 507-513.
225. Crikis S, Lu B, Murray-Segal LM, et al., Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 2010; 10: 2586-2595.
226. Ahrens HE, Petersen B, Herrmann D, et al., siRNA mediated knockdown of tissue factor expression in pigs for xenotransplantation. Am J Transplant 2015; 15: 1407-1414.
227. Robson SC, Candinas D, Siegel JB, et al., Potential mechanism of abnormal thromboregulation in xenograft rejection: loss of ecto-ATPases upon endothelial cell activation. Transplant Proc 1996; 28: 536.
228. Dor FJ, Kuwaki K, Tseng YL, et al., Potential of aspirin to inhibit thrombotic microangiopathy in alpha1,3-galactosyltransferase gene-knockout pig hearts after transplantation in baboons. Transplant Proc 2005; 37: 489-490.
229. Kim H, Hawthorne WJ, Kang HJ, et al., Human thrombomodulin regulates complement activation as well as the coagulation cascade in xeno-immune response. Xenotransplantation 2015; 22: 260-272.
230. Mueller NJ, Barth RN, Yamamoto S, et al., Activation of cytomegalovirus in pig-to-primate organ xenotransplantation. J Virol 2002; 76: 4734-4740.
231. Mueller NJ, Kuwaki K, Dor FJ, et al., Reduction of consumptive coagulopathy using porcine cytomegalovirus-free cardiac porcine grafts in pig-to-primate xenotransplantation. Transplantation 2004; 78: 1449-1453.
232. Mueller NJ, Kuwaki K, Knosalla C, et al., Early weaning of piglets fails to exclude porcine lymphotropic herpesvirus. Xenotransplantation 2005; 12: 59-62.
233. Gollackner B, Mueller NJ, Houser S, et al., Porcine cytomegalovirus and coagulopathy in pig-to-primate xenotransplantation. Transplantation 2003; 75: 1841-1847.
234. Yamada K, Tasaki M, Sekijima M, et al., Porcine cytomegalovirus infection is associated with early rejection of kidney grafts in a pig to baboon xenotransplantation model. Transplantation 2014; 98: 411-418.
235. Mueller NJ, Sulling K, Gollackner B, et al., Reduced efficacy of ganciclovir against porcine and baboon cytomegalovirus in pig-to-baboon xenotransplantation. Am J Transplant 2003; 3: 1057-1064.
236. Mueller NJ, Livingston C, Knosalla C, et al., Activation of porcine cytomegalovirus, but not porcine lymphotropic herpesvirus, in pig-to-baboon xenotransplantation. J Infect Dis 2004; 189: 1628-1633.
237. Mueller NJ, Ezzelarab M, Buhler L, et al., Monitoring of porcine and baboon cytomegalovirus infection in xenotransplantation. Xenotransplantation 2009; 16: 535-536.
238. Iwase H, Ekser B, Zhou H, et al., Further evidence for a sustained systemic inflammatory response in xenograft recipients (SIXR). Xenotransplantation 2015; 22: 399-405.
239. Esmon CT,. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32 (Suppl 1): 49-60.
240. Esmon CT,. The discovery of the endothelial cell protein C receptor. J Thromb Haemost 2010; 8: 2-5.
241. Esmon CT, Xu J, Lupu F,. Innate immunity and coagulation. J Thromb Haemost 2011; 9 (Suppl 1): 182-188.
242. Esmon CT,. Protein C anticoagulant system-anti-inflammatory effects. Semin Immunopathol 2012; 34: 127-132.
243. Ezzelarab M, Welchons D, Torres C, et al., Atorvastatin down-regulates the primate cellular response to porcine aortic endothelial cells in vitro. Transplantation 2008; 86: 733-737.
244. Lin CC, Ezzelarab M, Hara H, et al., Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-nonGal IgG binding to porcine aortic endothelial cells. J Thromb Haemost 2010; 8: 2001-2010.
245. Ezzelarab M, Ayares D, Cooper DK,. The potential of genetically-modified pig mesenchymal stromal cells in xenotransplantation. Xenotransplantation 2010; 17: 3-5.
246. Li J, Ezzelarab MB, Ayares D, Cooper DK,. The potential role of genetically-modified pig mesenchymal stromal cells in xenotransplantation. Stem Cell Rev 2014; 10: 79-85.
247. Kumar G, Hara H, Long C, et al., Adipose-derived mesenchymal stromal cells from genetically modified pigs: immunogenicity and immune modulatory properties. Cytotherapy 2012; 14: 494-504.
248. Oropeza M, Petersen B, Carnwath JW, et al., Transgenic expression of the human A20 gene in cloned pigs provides protection against apoptotic and inflammatory stimuli. Xenotransplantation 2009; 16: 522-534.
249. Petersen B, Lucas-Hahn A, Lemme E, et al., Generation and characterization of pigs transgenic for human hemeoxygenase-1 (hHO-1). Xenotransplantation 2010; 17: 102-103.
250. Petersen B, Ramackers W, Lucas-Hahn A, et al., Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys. Xenotransplantation 2011; 18: 355-368.
251. Schwinzer R, Baars W, Borns K, et al., Over-expression of human HO-1 and A20 in porcine cells: effects on susceptibility to cell-mediated lysis and inflammatory cytokines. Xenotransplantation 2011; 18: 269 (Abstract #122).
252. Ahrens HE, Petersen B, Ramackers W, et al., Kidneys from alpha1,3-galactosyltransferase knockout/human heme oxygenase-1/human A20 transgenic pigs are protected from rejection during ex vivo perfusion with human blood. Transplant Direct 2015; 1: e23.
253. Ide K, Ohdan H, Kobayashi T, et al., Antibody- and complement-independent phagocytotic and cytolytic activities of human macrophages toward porcine cells. Xenotransplantation 2005; 12: 181-188.
254. Burlak C, Twining LM, Rees MA,. Terminal sialic acid residues on human glycophorin A are recognized by porcine kupffer cells. Transplantation 2005; 80: 344-352.
255. Rees MA, Butler AJ, Brons IG, et al., Evidence of macrophage receptors capable of direct recognition of xenogeneic epitopes without opsonization. Xenotransplantation 2005; 12: 13-19.
256. Ekser B, Echeverri GJ, Hassett AC, et al., Hepatic function after genetically engineered pig liver transplantation in baboons. Transplantation 2010; 90: 483-493.
257. Ekser B, Long C, Echeverri GJ, et al., Impact of thrombocytopenia on survival of baboons with genetically modified pig liver transplants: clinical relevance. Am J Transplant 2010; 10: 273-285.
258. Ekser B, Klein E, He J, et al., Genetically-engineered pig-to-baboon liver xenotransplantation: histopathology of xenografts and native organs. PLoS ONE 2012; 7: e29720.
259. Ekser B, Burlak C, Waldman JP, et al., Immunobiology of liver xenotransplantation. Expert Rev Clin Immunol 2012; 8: 621-634.
260. Ezzelarab M, Ekser B, Gridelli B, et al., Thrombocytopenia after pig-to-baboon liver xenotransplantation: where do platelets go? Xenotransplantation 2011; 18: 320-327.
261. Bush EL, Barbas AS, Holzknecht ZE, et al., Coagulopathy in alpha-galactosyl transferase knockout pulmonary xenotransplants. Xenotransplantation 2011; 18: 6-13.
262. Lamattina JC, Burdorf L, Zhang T, et al., Pig-to-baboon liver xenoperfusion utilizing GalTKO.hCD46 pigs and glycoprotein Ib blockade. Xenotransplantation 2014; 21: 274-286.
263. Burlak C, Paris LL, Chihara RK, et al., The fate of human platelets perfused through the pig liver: implications for xenotransplantation. Xenotransplantation 2010; 17: 350-361.
264. Burdorf L, Stoddard T, Zhang T, et al., Expression of human CD46 modulates inflammation associated with GalTKO lung xenograft injury. Am J Transplant 2014; 14: 1084-1095.
265. Yeh H, Machaidze Z, Wamala I, et al., Increased transfusion-free survival following auxiliary pig liver xenotransplantation. Xenotransplantation 2014; 21: 454-464.
266. Harris DG, Quinn KJ, French BM, et al., Meta-analysis of the independent and cumulative effects of multiple genetic modifications on pig lung xenograft performance during ex vivo perfusion with human blood. Xenotransplantation 2015; 22: 102-111.
267. Paris LL, Estrada JL, Li P, et al., Reduced human platelet uptake by pig livers deficient in the asialoglycoprotein receptor 1 protein. Xenotransplantation 2015; 22: 203-210.
268. Cantu E, Balsara KR, Li B, et al., Prolonged function of macrophage, von Willebrand factor-deficient porcine pulmonary xenografts. Am J Transplant 2007; 7: 66-75.
269. Hara H, Campanile N, Tai HC, et al., An in vitro model of pig liver xenotransplantation-pig complement is associated with reduced lysis of wild-type and genetically modified pig cells. Xenotransplantation 2010; 17: 370-378.
270. Hara H, Gridelli B, Lin YJ, Marcos A, Cooper DK,. Liver xenografts for the treatment of acute liver failure: clinical and experimental experience and remaining immunologic barriers. Liver Transpl 2008; 14: 425-434.
271. Bouhours D, Pourcel C, Bouhours JE,. Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Gal alpha 1-3Gal), blood group H determinant and N-glycolylneuraminic acid. Glycoconj J 1996; 13: 947-953.
272. Zhu A, Hurst R,. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002; 9: 376-381.
273. Salama A, Evanno G, Harb J, Soulillou JP,. Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation. Xenotransplantation 2015; 22: 85-94.
274. Miwa Y, Kobayashi T, Nagasaka T, et al., Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation? Xenotransplantation 2004; 11: 247-253.
275. Bardor M, Nguyen DH, Diaz S, Varki A,. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 2005; 280: 4228-4237.
276. Padler-Karavani V, Varki A,. Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation 2011; 18: 1-5.
277. Springer SA, Diaz SL, Gagneux P,. Parallel evolution of a self-signal: humans and new world monkeys independently lost the cell surface sugar Neu5Gc. Immunogenetics 2014; 66: 671-674.
278. Burlak C, Paris LL, Lutz AJ, et al., Reduced binding of human antibodies to cells from GGTA1/CMAH KO pigs. Am J Transplant 2014; 14: 1895-1900.
279. Lutz AJ, Li P, Estrada JL, et al., Double knockout pigs deficient in N-glycolylneuraminic acid and galactose alpha-1,3-galactose reduce the humoral barrier to xenotransplantation. Xenotransplantation 2013; 20: 27-35.
280. Estrada JL, Martens G, Li P, et al., Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA1/CMAH/beta4GalNT2 genes. Xenotransplantation 2015; 22: 194-202.
281. Lee W, Hara H, Ezzelarab MB, et al., Initial in vitro studies on tissues and cells from GTKO/hCD46/NeuGcKO pigs. Xenotransplantation. In press
282. Soin B, Smith KG, Zaidi A, et al., Physiological aspects of pig-to-primate renal xenotransplantation. Kidney Int 2001; 60: 1592-1597.
283. Ibrahim Z, Busch J, Awwad M, et al., Selected physiologic compatibilities and incompatibilities between human and porcine organ systems. Xenotransplantation 2006; 13: 488-499.
284. Soin B, Ostlie D, Cozzi E, et al., Growth of porcine kidneys in their native and xenograft environment. Xenotransplantation 2000; 7: 96-100.
285. Groth CG, Korsgren O, Tibell A, et al., Transplantation of porcine fetal pancreas to diabetic patients. Lancet 1994; 344: 1402-1404.
286. van der Windt DJ, Bottino R, Kumar G, et al., Clinical islet xenotransplantation: how close are we? Diabetes 2012; 61: 3046-3055.
287. Martin C, Plat M, Nerriere-Daguin V, et al., Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation. Transgenic Res 2005; 14: 373-384.
288. Leveque X, Cozzi E, Naveilhan P, Neveu I,. Intracerebral xenotransplantation: recent findings and perspectives for local immunosuppression. Curr Opin Organ Transplant 2011; 16: 190-194.
289. Hara H, Cooper DK,. The immunology of corneal xenotransplantation: a review of the literature. Xenotransplantation 2010; 17: 338-349.
290. Hara H, Cooper DK,. Xenotransplantation-the future of corneal transplantation? Cornea 2011; 30: 371-378.
291. Kim MK, Wee WR, Park CG, Kim SJ,. Xenocorneal transplantation. Curr Opin Organ Transplant 2011; 16: 231-236.
292. Choi HJ, Kim MK, Lee HJ, et al., Efficacy of pig-to-rhesus lamellar corneal xenotransplantation. Invest Ophthalmol Vis Sci 2011; 52: 6643-6650.
293. Choi HJ, Lee JJ, Kim MK, et al., Cross-reactivity between decellularized porcine corneal lamellae for corneal xenobridging and subsequent corneal allotransplants. Xenotransplantation 2014; 21: 115-123.
294. Lamm V, Hara H, Mammen A, Dhaliwal D, Cooper DK,. Corneal blindness and xenotransplantation. Xenotransplantation 2014; 21: 99-114.
295. Long C, Hara H, Pawlikowski Z, et al., Genetically engineered pig red blood cells for clinical transfusion: initial in vitro studies. Transfusion 2009; 49: 2418-2429.
296. Cooper DK, Hara H, Yazer M,. Genetically engineered pigs as a source for clinical red blood cell transfusion. Clin Lab Med 2010; 30: 365-380.
297. Wang ZY, Burlak C, Estrada JL, et al., Erythrocytes from GGTA1/CMAH knockout pigs: implications for xenotransfusion and testing in non-human primates. Xenotransplantation 2014; 21: 376-384.
298. Eckermann JM, Buhler LH, Zhu A, et al., Initial investigation of the potential of modified porcine erythrocytes for transfusion in primates. Xenotransplantation 2004; 11: 18-26.
299. Rouhani FJ, Dor FJ, Cooper DK,. Investigation of red blood cells from alpha1,3-galactosyltransferase-knockout pigs for human blood transfusion. Transfusion 2004; 44: 1004-1012.
300. Matsumoto S, Tan P, Baker J, et al., Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant Proc 2014; 46: 1992-1995.
301. Wynyard S, Nathu D, Garkavenko O, Denner J, Elliott R,. Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. Xenotransplantation 2014; 21: 309-323.
302. Zhang MC, Liu X, Jin Y, et al., Lamellar keratoplasty treatment of fungal corneal ulcers with acellular porcine corneal stroma. Am J Transplant 2015; 15: 1068-1075.
303. Kirchhof N, Shibata S, Wijkstrom M, et al., Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation 2004; 11: 396-407.
304. Soderlund J, Wennberg L, Castanos-Velez E, et al., Fetal porcine islet-like cell clusters transplanted to cynomolgus monkeys: an immunohistochemical study. Transplantation 1999; 67: 784-791.
305. Dor FJ, Cheng J, Alt A, Cooper DK, Schuurman HJ,. Gal alpha 1,3Gal expression on porcine pancreatic islets, testis, spleen, and thymus. Xenotransplantation 2004; 11: 101-106.
306. Korbutt GS, Elliott JF, Ao Z, et al., Large scale isolation, growth, and function of porcine neonatal islet cells. J Clin Invest 1996; 97: 2119-2129.
307. Emamaullee JA, Shapiro AM, Rajotte RV, Korbutt G, Elliott JF,. Neonatal porcine islets exhibit natural resistance to hypoxia-induced apoptosis. Transplantation 2006; 82: 945-952.
308. Murray AG, Nelson RC, Rayat GR, Elliott JF, Korbutt GS,. Neonatal porcine islet cells induce human CD4+, but not CD8+, lymphocyte proliferation and resist cell-mediated cytolytic injury in vitro. Diabetes 1999; 48: 1713-1719.
309. Nagaraju S, Bottino R, Wijkstrom M, Trucco M, Cooper DK,. Islet xenotransplantation: what is the optimal age of the islet-source pig? Xenotransplantation 2015; 22: 7-19.
310. Rayat GR, Rajotte RV, Hering BJ, Binette TM, Korbutt GS,. In vitro and in vivo expression of Galalpha-(1,3)Gal on porcine islet cells is age dependent. J Endocrinol 2003; 177: 127-135.
311. Thompson P, Badell IR, Lowe M, et al., Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. Am J Transplant 2011; 11: 2593-2602.
312. McKenzie IF, Koulmanda M, Mandel TE, Sandrin MS,. Pig islet xenografts are susceptible to "anti-pig" but not Gal alpha(1,3)Gal antibody plus complement in Gal o/o mice. J Immunol 1998; 161: 5116-5119.
313. Komoda H, Miyagawa S, Kubo T, et al., A study of the xenoantigenicity of adult pig islets cells. Xenotransplantation 2004; 11: 237-246.
314. Komoda H, Miyagawa S, Omori T, et al., Survival of adult islet grafts from transgenic pigs with N-acetylglucosaminyltransferase-III (GnT-III) in cynomolgus monkeys. Xenotransplantation 2005; 12: 209-216.
315. Wijkstrom M, Bottino R, Iwase H, et al., Glucose metabolism in pigs expressing human genes under an insulin promoter. Xenotransplantation 2015; 22: 70-79.
316. Nagaraju S, Bottino R, Wijkstrom M, et al., Islet xenotransplantation from genetically engineered pigs. Curr Opin Organ Transplant 2013; 18: 695-702.
317. Shin JS, Kim JM, Kim JS, et al., Long-term control of diabetes in immunosuppressed nonhuman primates (NHP) by the transplantation of adult porcine islets. Am J Transplant 2015; 15: 2837-2850.
318. Buhler L, Deng S, O'Neil J, et al., Adult porcine islet transplantation in baboons treated with conventional immunosuppression or a non-myeloablative regimen and CD154 blockade. Xenotransplantation 2002; 9: 3-13.
319. Hering BJ, Wijkstrom M, Graham ML, et al., Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006; 12: 301-303.
320. Cardona K, Milas Z, Strobert E, et al., Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am J Transplant 2007; 7: 2260-2268.
321. van der Windt DJ, Bottino R, Casu A, et al., Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009; 9: 2716-2726.
322. Cardona K, Korbutt GS, Milas Z, et al., Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006; 12: 304-306.
323. Thompson P, Cardona K, Russell M, et al., CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant 2011; 11: 947-957.
324. Perez-Basterrechea M, Obaya AJ, Meana A, Otero J, Esteban MM,. Cooperation by fibroblasts and bone marrow-mesenchymal stem cells to improve pancreatic rat-to-mouse islet xenotransplantation. PLoS ONE 2013; 8: e73526.
325. Li J, Ezzelarab MB, Cooper DK,. Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation. Xenotransplantation 2012; 19: 273-285.
326. Li J, Andreyev O, Chen M, et al., Human T cells upregulate CD69 after coculture with xenogeneic genetically-modified pig mesenchymal stromal cells. Cell Immunol 2013; 285: 23-30.
327. Dufour JM, Rajotte RV, Korbutt GS, Emerich DF,. Harnessing the immunomodulatory properties of Sertoli cells to enable xenotransplantation in type I diabetes. Immunol Invest 2003; 32: 275-297.
328. Dufour JM, Rajotte RV, Kin T, Korbutt GS,. Immunoprotection of rat islet xenografts by cotransplantation with sertoli cells and a single injection of antilymphocyte serum. Transplantation 2003; 75: 1594-1596.
329. Gores PF, Hayes DH, Copeland MJ, et al., Long-term survival of intratesticular porcine islets in nonimmunosuppressed beagles. Transplantation 2003; 75: 613-618.
330. Halberstadt C, Emerich DF, Gores P,. Use of Sertoli cell transplants to provide local immunoprotection for tissue grafts. Expert Opin Biol Ther 2004; 4: 813-825.
331. Wang DZ, Skinner S, Elliot R, et al., Xenotransplantation of neonatal porcine islets and Sertoli cells into nonimmunosuppressed streptozotocin-induced diabetic rats. Transplant Proc 2005; 37: 470-471.
332. Ramji QA, Bayrack K, Arefanian H, et al., Protection of porcine islet xenografts in mice using sertoli cells and monoclonal antibodies. Transplantation 2011; 92: 1309-1315.
333. Bennet W, Sundberg B, Lundgren T, et al., Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation 2000; 69: 711-719.
334. Moberg L, Johansson H, Lukinius A, et al., Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360: 2039-2045.
335. Ozmen L, Ekdahl KN, Elgue G, et al., Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002; 51: 1779-1784.
336. Johansson H, Lukinius A, Moberg L, et al., Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54: 1755-1762.
337. Goto M, Tjernberg J, Dufrane D, et al., Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation 2008; 15: 225-234.
338. Ji M, Yi S, Smith-Hurst H, et al., The importance of tissue factor expression by porcine NICC in triggering IBMIR in the xenograft setting. Transplantation 2011; 91: 841-846.
339. van der Windt DJ, Bottino R, Casu A, Campanile N, Cooper DK,. Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation 2007; 14: 288-297.
340. van der Windt DJ, Marigliano M, He J, et al., Early islet damage after direct exposure of pig islets to blood: has humoral immunity been underestimated? Cell Transplant 2012; 21: 1791-1802.
341. Nagaraju S, Bertera S, Tanaka T, et al., In vitro exposure of pig neonatal islet-like cell clusters to human blood. Xenotransplantation 2015; 22: 317-324.
342. Echeverri GJ, McGrath K, Bottino R, et al., Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. Am J Transplant 2009; 9: 2485-2496.
343. Fujita M, McGrath KM, Bottino R, et al., Technique of endoscopic biopsy of islet allografts transplanted into the gastric submucosal space in pigs. Cell Transplant 2013; 22: 2335-2344.
344. Christoffersson G, Henriksnas J, Johansson L, et al., Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes 2010; 59: 2569-2578.
345. Berman DM, O'Neil JJ, Coffey LC, et al., Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold. Am J Transplant 2009; 9: 91-104.
346. Dufrane D, Goebbels RM, Gianello P,. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation 2010; 90: 1054-1062.
347. Casu A, Bottino R, Balamurugan AN, et al., Metabolic aspects of pig-to-monkey (Macaca fascicularis) islet transplantation: implications for translation into clinical practice. Diabetologia 2008; 51: 120-129.
348. Casu A, Echeverri GJ, Bottino R, et al., Insulin secretion and glucose metabolism in alpha 1,3-galactosyltransferase knock-out pigs compared to wild-type pigs. Xenotransplantation 2010; 17: 131-139.
349. Potter KJ, Abedini A, Marek P, et al., Islet amyloid deposition limits the viability of human islet grafts but not porcine islet grafts. Proc Natl Acad Sci USA 2010; 107: 4305-4310.
350. Tseng YL, Sachs DH, Cooper DK,. Porcine hematopoietic progenitor cell transplantation in nonhuman primates: a review of progress. Transplantation 2005; 79: 1-9.
351. Tseng YL, Dor FJ, Kuwaki K, et al., Bone marrow transplantation from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Xenotransplantation 2004; 11: 361-370.
352. Tasaki M, Wamala I, Tena A, et al., High incidence of xenogenic bone marrow engraftment in pig-to-baboon intra-bone bone marrow transplantation. Am J Transplant 2015; 15: 974-983.
353. Barth RN, Yamamoto S, Lamattina JC, et al., Xenogeneic thymokidney and thymic tissue transplantation in a pig-to-baboon model: I. Evidence for pig-specific T-cell unresponsiveness. Transplantation 2003; 75: 1615-1624.
354. Yamamoto S, Lavelle JM, Vagefi PA, et al., Vascularized thymic lobe transplantation in a pig-to-baboon model: a novel strategy for xenogeneic tolerance induction and T-cell reconstitution. Transplantation 2005; 80: 1783-1790.
355. Griesemer AD, Hirakata A, Shimizu A, et al., Results of gal-knockout porcine thymokidney xenografts. Am J Transplant 2009; 9: 2669-2678.
356. Tena A, Vallabhajosyula P, Hawley RJ, et al., Quantification of baboon thymopoiesis in porcine thymokidney xenografts by the signal-joining T-cell receptor excision circle assay. Transplantation 2011; 91: 639-644.
357. Tena A, Kurtz J, Leonard DA, et al., Transgenic expression of human CD47 markedly increases engraftment in a murine model of pig-to-human hematopoietic cell transplantation. Am J Transplant 2014; 14: 2713-2722.
358. Bibikova M, Golic M, Golic KG, Carroll D,. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 2002; 161: 1169-1175.
359. Carroll D,. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther 2008; 15: 1463-1468.
360. Klug A,. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem 2010; 79: 213-231.
361. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD,. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010; 11: 636-646.
362. Watanabe M, Umeyama K, Matsunari H, et al., Knockout of exogenous EGFP gene in porcine somatic cells using zinc-finger nucleases. Biochem Biophys Res Commun 2010; 402: 14-18.
363. Hauschild J, Petersen B, Santiago Y, et al., Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases. Proc Natl Acad Sci USA 2011; 108: 12013-12017.
364. Tesson L, Usal C, Menoret S, et al., Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol 2011; 29: 695-696.
365. Galli C, Perota A, Brunetti D, et al., Genetic engineering including superseding microinjection: new ways to make GM pigs. Xenotransplantation 2010; 17: 397-410.
366. Hsu PD, Lander ES, Zhang F,. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157: 1262-1278.
367. Doudna JA, Charpentier E,. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014; 346: 1258096.
368. Ni W, Qiao J, Hu S, et al., Efficient gene knockout in goats using CRISPR/Cas9 system. PLoS ONE 2014; 9: e106718.
369. Mali P, Esvelt KM, Church GM,. Cas9 as a versatile tool for engineering biology. Nat Methods 2013; 10: 957-963.
370. Seruggia D, Montoliu L,. The new CRISPR-Cas system: RNA-guided genome engineering to efficiently produce any desired genetic alteration in animals. Transgenic Res 2014; 23: 707-716.
371. Kim H, Kim JS,. A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014; 15: 321-334.
372. Li P, Estrada JL, Burlak C, et al., Efficient generation of genetically distinct pigs in a single pregnancy using multiplexed single-guide RNA and carbohydrate selection. Xenotransplantation 2015; 22: 20-31.
373. Ayares D, Vaught T, Ball S, et al., Genetic engineering of source pigs for xenotransplantation: progress and prospects. Xenotransplantation 2013; 20: 361 (Abstract 408).
374. Cooper DK,. The case for xenotransplantation. Clin Transplant 2015; 29: 288-293.